Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation.
The endocannabinoid anandamide is an emerging potential signalling molecule in the cardiovascular system. Anandamide causes vasodilatation, bradycardia and hypotension in animals and has been implicated in the pathophysiology of endotoxic, haemorrhagic and cardiogenic shock, but its vascular effects have not been studied in man. Human forearm blood flow and skin microcirculatory flow were recorded using venous occlusion plethysmography and laser-Doppler perfusion imaging (LDPI), respectively. Each test drug was infused into the brachial artery or applied topically on the skin followed by a standardized pin-prick to disrupt the epidermal barrier. Anandamide failed to affect forearm blood flow when administered intra-arterially at infusion rates of 0.3-300 nmol min(-1). The highest infusion rate led to an anandamide concentration of approximately 1 microM in venous blood as measured by mass spectrometry. Dermal application of anandamide significantly increased skin microcirculatory flow and coapplication of the transient receptor potential vanilloid 1 (TRPV1) antagonist capsazepine inhibited this effect. The TRPV1 agonists capsaicin, olvanil and arvanil all induced concentration-dependent increases in skin blood flow and burning pain when administered dermally. Coapplication of capsazepine inhibited blood flow and pain responses to all three TRPV1 agonists. This study shows that locally applied anandamide is a vasodilator in the human skin microcirculation. The results are consistent with this lipid being an activator of TRPV1 on primary sensory nerves, but do not support a role for anandamide as a circulating vasoactive hormone in the human forearm vascular bed.
Movahed
Pouya
P
Department of Clinical and Experimental Pharmacology, Lund University Hospital, SE-221 85 Lund, Sweden.
Evilevitch
Vladimir
V
Andersson
Tomas L G
TL
Jönsson
Bo A G
BA
Wollmer
Per
P
Zygmunt
Peter M
PM
Högestätt
Edward D
ED
D000328:Adult; D001095:Arachidonic Acids / Q000493:pharmacokinetics / Q000494:pharmacology*; D001596:Benzylamines / Q000494:pharmacology*; D002211:Capsaicin / Q000031:analogs & derivatives / Q000494:pharmacology; D063388:Endocannabinoids; D005260:Female; D005542:Forearm / Q000098:blood supply*; D006801:Humans; D017078:Laser-Doppler Flowmetry; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000098:blood supply; D010991:Plethysmography; D053284:Polyunsaturated Alkamides; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply* / Q000187:drug effects; D050916:TRPV Cation Channels / Q000819:agonists
D001095:Arachidonic Acids; D001596:Benzylamines; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D050916:TRPV Cation Channels; C494482:TRPV1 protein, human; C121153:arvanil; C054256:olvanil; C071423:capsazepine; D002211:Capsaicin; C078814:anandamide